Compile Data Set for Download or QSAR
Report error Found 543 Enz. Inhib. hit(s) with all data for entry = 10676
TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559127(US11370774, Compound 241c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559128(US11370774, Compound 242b | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559133(US11370774, Compound 246b | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559134(US11370774, Compound 247b | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559131(US11370774, Compound 245g | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559137(US11370774, Compound 236d | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559138(US11370774, Compound 12c | US11708347, Compound 12...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559135(US11370774, Compound 248c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559136(US11370774, Compound 249f | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559141(US11370774, Compound 24b | US11708347, Compound 24...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559142(US11370774, Compound 38f | US11708347, Compound 38...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559139(US11370774, Compound 22a | US11708347, Compound 22...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559140(US11370774, Compound 256c)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559112(US11370774, Compound 220g | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559113(US11370774, Compound 221c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559110(US11370774, Compound 229b | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559111(US11370774, Compound 219c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559116(US11370774, Compound 231c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559117(US11370774, Compound 232c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559121(US11370774, Compound 234f | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM558996(US11370774, Compound 98g | US11370774, Compound 98...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559119(US11370774, Compound 233c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559102(US11370774, Compound 238c | US11370774, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM558996(US11370774, Compound 98g | US11370774, Compound 98...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559126(US11370774, Compound 240d | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559123(US11370774, Compound 235b | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559124(US11370774, Compound 239c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559162(US11370774, Compound 350e | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559160(US11370774, Compound 332e | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559166(US11370774, Compound 360c | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559167(US11370774, Compound 268h | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559164(US11370774, Compound 337b | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559170(US11370774, Compound 262c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559171(US11370774, Compound 263c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559168(US11370774, Compound 461c | US11708347, Compound 4...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559169(US11370774, Compound 261c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559174(US11370774, Compound 361c | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559172(US11370774, Compound 431c)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559173(US11370774, Compound 310c | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559145(US11370774, Compound 252d | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559143(US11370774, Compound 101c | US11708347, Compound 1...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559149(US11370774, Compound 254c | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559147(US11370774, Compound 253f)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559148(US11370774, Compound 90d | US11708347, Compound 90...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559074(US11370774, Compound 258f | US11370774, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559074(US11370774, Compound 258f | US11370774, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559151(US11370774, Compound 329b | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559152(US11370774, Compound 330c | US11708347, Compound 3...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559157(US11370774, Compound 409f | US11708347, Compound 4...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetComplement factor D(Human)
Biocryst Pharmaceuticals

US Patent
LigandPNGBDBM559158(US11370774, Compound 267h | US11708347, Compound 2...)
Affinity DataIC50: 1.00E+3nMAssay Description:An established esterolytic assay for the measurement of Factor D activity and inhibition of Factor D activity was used (Kam, C. M.; McRae, B. J.; Har...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

Displayed 1 to 50 (of 543 total ) | Next | Last >>
Jump to: